About Us

Established in 1989 as a spin out from Queen Mary University, London, hVIVO, part of Open Orphan plc is a trusted partner and industry-leading clinical development services business pioneering human disease models based upon viral challenge. Using human challenge studies to establish early proof-of-concept, hVIVO’s clinical trial platform can accelerate drug and vaccine development in respiratory and infectious disease.

hVIVO conducts studies and provides services for customers, both pharmaceutical and biotech companies, utilising a range of different client trial and laboratory methodologies across differing viral challenges. Experience and know-how from over 50 challenge studies is applied to ensure effective study design and excellent service delivery for customers.

The Company has a leading portfolio of 9 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough, 1 COPD, 1 COVID, 1 Malaria viral challenge models. As announced in early March 2020, hVIVO is rapidly advancing a number of Coronavirus challenge study models and expects to be helping many COVID-19 vaccine development companies to test their vaccines.

In January 2020, hVIVO merged with Open Orphan plc a rapidly growing niche CRO pharmaceutical services company which comprises of two commercial specialist CRO services businesses hVIVO and Venn Life Sciences and is developing an early stage orphan drug genomics data platform business. This platform captures valuable genetic data from patient populations with specific diseases with designated orphan drug status and incorporating AI tools. Venn, as an integrated drug development consultancy, offers CMC (chemistry, manufacturing and controls), preclinical, Phase I & II clinical trials design and execution. The merger with hVIVO created a European full pharma services company broadening the Company’s customer base and with complementary specialist CRO services, widened the range of the Company’s service offerings.

The combination of Open Orphan, hVIVO and Venn Life Sciences has resulted in the creation of a true pioneer for the worldwide fight against COVID-19. This has been reflected in some recent announcements such as the Phase I Codagenix COVID-19 vaccine candidate, the Nearmedic COVID-19 anti-viral and also the launch of the hVIVO COVID Clear offering.